Clinical Trial: STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038915) titled 'STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1' on June 18.

Brief Summary: To learn if the drug combination of tiragolumab and ivonescimab can help to control LSCC that got worse after standard treatment with platinum doublets and anti-PD-1/PD-L1 therapy.

Study Start Date: Dec. 03, 2025

Study Type: INTERVENTIONAL

Condition: Lung Squamous Cell Carcinoma Anti-PD1/PDL1 Antibody

Intervention: DRUG: Tiragolumab

Given by IV

DRUG: Ivonescimab

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Spon...